Access our full library of guidance, white papers, and other resources developed by and for the medical technology industry.
AdvaMed’s® Comment Letter to ASTP/ONC, outlines concrete policy reforms across FDA oversight, CMS payment pathways, and HIPAA data-sharing rules to accelerate patient access to AI-enabled medical technologies. As AI-enabled medical…
Explore the 2026 State Policy Briefing Series for insights on medtech policy, legislative activity, and regulatory updates impacting the medtech industry.
AdvaMed® comment letter to the OIG’s recommends updates to safe harbors, value-based arrangements, & oversight to support value-driven healthcare.
As tariff uncertainty continues in 2025, AdvaMed plays tariff chess, advocating for predictable, zero-for-zero policies to protect medtech innovation and access.
AdvaMed® Advancements: Q4 2025 Report highlights how unified industry advocacy responded to policy disruption, trade uncertainty, and federal action impacting medtech.
Brought to you by AdvaMed®, Medtech POV with Scott Whitaker is a podcast that covers the intersection of medtech and policy from every perspective.
Read how shifting to a capability-driven procurement model enables medtech organizations to better align sourcing decisions with business strategy, and strengthen cross-functional collaboration.
This comment letter from AdvaMed responds to the OSTP’s Request for Information on National Strategic Plan for Advanced Manufacturing (“OSTP RFI”).
AdvaMed® Advancements: Q3 2025 Report. Amid an increasingly charged political environment, AdvaMed remained a steady, persuasive voice for medtech innovation. From mobilizing rapid action on the Section 232 investigation to…
AdvaMed® periodically compiles benchmarking data on Member companies’ policies regarding the provision of meals and refreshments to U.S. Health Care Professionals to assist companies in understanding industry trends and practices…